- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04921215
Teen Sleep and Light Study
January 30, 2024 updated by: Rush University Medical Center
Adolescent Circadian Misalignment: Mechanistic Studies of Sleep and Light
Circadian clocks shift later (delay) with the progression of puberty; this shift contributes to late sleep onsets in older adolescents.
Early school start times, however, force teenagers to awaken earlier than their spontaneous wake time and the opportunity for sleep shortens.
Chronic circadian misalignment and sleep restriction are at their peak during late adolescence, and are associated with various negative outcomes.
Morning bright light exposure from light boxes can shift rhythms earlier (phase advance) to facilitate earlier sleep onset, and reduce circadian misalignment and the associated risks.
Studies of adults, however, indicate that restricted sleep and exposure to evening light due to late bedtimes make morning bright light less effective in producing advances.
Pilot data collected from adolescents mimic this finding, but also suggest that staying awake late in normal household lighting and the subsequent sleep restriction before and during a 3-day morning bright light regimen, can shift the system in the wrong direction (phase delay).
The overarching goal of this study is to examine the dose of sleep restriction and evening household light that prevents the desired phase advance to morning bright light in adolescents aged 14-17 years.
Study 1 aims to construct a sleep restriction with normal household evening light dose-response curve to determine the point at which morning bright light begins to lose its effectiveness.
The investigators hypothesize that the circadian system will advance with sufficient sleep, but with increasing sleep restriction/evening light, circadian rhythms will not shift or will delay despite the phase advancing morning bright light.
Study 2 will test whether reducing evening light exposure by wearing sunglasses before bedtime during sleep restriction can facilitate phase advances.
The main outcome measures to build the dose-response curve will be phase shifts of the central circadian clock marked by the dim light melatonin onset (DLMO) and total sleep time measured from actigraphy in the laboratory.
Secondary outcomes include cognitive performance, sleepiness, and mood.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Circadian clocks shift later (delay) with the progression of puberty; this shift contributes to late sleep onsets in older adolescents.
Early school start times, however, force teenagers to awaken earlier than their spontaneous wake time and the opportunity for sleep shortens.
Indeed, a majority of adolescents in the U.S. are chronically sleep deprived, getting 1-2 hours less sleep than recommended.
Also, many adolescents wake for school at the "wrong" circadian time.
Chronic circadian misalignment and sleep restriction are at their peak during late adolescence, and are associated with morning daytime sleepiness, poor academic performance, conduct problems, depressed mood, suicidal ideation, substance use, and obesity.
Morning bright light exposure from light boxes can shift rhythms earlier (phase advance) to facilitate earlier sleep onset, and reduce circadian misalignment and the associated risks.
The investigators constructed the first phase response curve (PRC) to light for adolescents and determined that the optimal time for bright light exposure to produce phase advances was about 1 hour before habitual wake and light should be avoided around the time of habitual bedtime because it causes rhythms to shift later (delay).
Studies of adults, however, indicate that restricted sleep and exposure to evening light due to late bedtimes - two classic features of older adolescent sleep - make morning bright light less effective in producing advances.
Pilot data collected from adolescents mimic this finding, but also suggest that staying awake late in normal household lighting and the subsequent sleep restriction before and during a 3-day morning bright light regimen, can shift the system in the wrong direction (phase delay).
The overarching goal of this study is to examine the dose of sleep restriction and evening household light that prevents the desired phase advance to morning bright light in adolescents aged 14-17 years.
Study 1 aims to construct a sleep restriction with normal household evening light dose-response curve to determine the point at which morning bright light begins to lose its effectiveness.
Following a baseline week with 10-hour sleep opportunities, participants will keep the same wake time but be randomly assigned to one of 4 bedtimes which will be the same or later than baseline to produce 4 levels of sleep restriction with evening light (0, 1.5, 3, or 4.5 hours).
After 2 nights, the sleep schedule will gradually shift earlier over 3 nights, and participants will receive bright light each morning.
The investigators hypothesize that the circadian system will advance with sufficient sleep, but with increasing sleep restriction/evening light, circadian rhythms will not shift or will delay despite the phase advancing morning bright light.
Study 2 will test whether reducing evening light exposure by wearing sunglasses before bedtime during sleep restriction can facilitate phase advances.
Study 2 will test the same 4 "doses" of sleep restriction.
The main outcome measures to build the dose-response curve will be phase shifts of the central circadian clock marked by the dim light melatonin onset (DLMO) and total sleep time measured from actigraphy in the laboratory.
Secondary outcomes include cognitive performance, sleepiness, and mood.
Study Type
Interventional
Enrollment (Estimated)
115
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Recruiting
- Rush University Medical Center, Biological Rhythms Research Laboratory
-
Principal Investigator:
- Stephanie Crowley, PhD
-
Contact:
- Stephanie Crowley, PhD
- Phone Number: 312-563-4783
- Email: Stephanie_Crowley@rush.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
14 years to 17 years (Child)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- 14-17 years old;
- Participants and parents have sufficient knowledge of the English language;
- Participants are fully vaccinated for COVID-19
Exclusion Criteria:
- personal history of a psychotic disorder, bipolar disorder, neurological disorder, psychopathology, sleep disorder (sleep apnea, restless legs syndrome, narcolepsy, insomnia), metabolic disorders, chronic medical conditions (e.g., cancer, diabetes, kidney disease, active asthma), or infectious illness;
- current illness, fever or symptoms of respiratory infection or allergy at the time of laboratory assessments;
- current use of prescribed mediations (except birth control pills);
- current use of melatonin or over-the-counter medications that can affect the sleep/wake cycle, daytime sleepiness, or suppress melatonin;
- physical handicap that interferes with the study (e.g., blind);
- mental retardation or other pervasive developmental disorder;
- symptoms of depressed mood based on a score of 16 or greater on the Center for Epidemiological Studies fro Depression (CES-D);
- suicidal ideation (past or current)
- travel beyond two time zones within a month of beginning the study;
- female participants who indicate symptoms of premenstrual dysphoric disorder (PMDD)
- unusual sleep lengths (means < 6 hours or > 10 hours);
- color blind as determined by the Ishihara color blindness test, or eye surgery to correct for lens curvature;
- positive test for illicit drugs or nicotine;
- positive test for alcohol at the beginning of the 7-day lab stay
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 0 hours of sleep restriction
Bedtime will be the same as baseline.
|
All participants will receive phase advancing morning bright light.
|
Experimental: 1.5 hours of sleep restriction
Bedtime will be 1.5 hours later than baseline.
|
All participants will receive phase advancing morning bright light.
|
Experimental: 3 hours of sleep restriction
Bedtime will be 3 hours later than baseline.
|
All participants will receive phase advancing morning bright light.
|
Experimental: 4.5 hours of sleep restriction
Bedtime will be 4.5 hours later than baseline.
|
All participants will receive phase advancing morning bright light.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dim Light Melatonin Onset (DLMO) phase shift
Time Frame: Change in DLMO phase from baseline (before experimental manipulation on days 9) to final phase assessment (after experimental manipulation on day 15)
|
Saliva sampling for the baseline DLMO will begin 8 hours before baseline bedtime and end 4 hours after baseline bedtime to capture the rise of endogenous melatonin.
Sampling for the final DLMO will begin 11 hours before baseline bedtime and end 4 hours after baseline bedtime.
Participants remain awake and seated in comfortable recliners in dim light, except when they need to use the adjoining restroom.
Saliva samples are collected every 30 minutes using Salivettes.
The samples are immediately centrifuged and frozen, and later shipped on dry ice to SolidPhase, Inc, when they are analyzed for melatonin using direct radioimmunoassay.
Investigators compute the DLMO using a 4 pg/ml threshold; the time at which melatonin values surpass this threshold is the DLMO.
Baseline - Final DLMO will define the phase shift of the central circadian clock.
|
Change in DLMO phase from baseline (before experimental manipulation on days 9) to final phase assessment (after experimental manipulation on day 15)
|
Sleep restriction dose
Time Frame: During the experimental manipulation (study nights 10-14)
|
Sleep will be monitored by wrist actigraphy in the laboratory.
Staff will document lights on and off times and any noticeable arousals to facilitate the most accurate sleep scoring.
Actigraphy data are collected in 1-minute epochs and will be analyzed at the low sensitivity setting using Actiware 6, as this setting produces the most valid results for adolescents aged 14 to 17 years.
The following variables will be computed: sleep start time, sleep end time, and total sleep time.
The average total sleep time of study nights 10-14 will be used to determine the "dose" of sleep restriction each participant received.
Sleep restriction dose will be defined as 10 hours - average total sleep time on study nights 10-14.
|
During the experimental manipulation (study nights 10-14)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 14, 2021
Primary Completion (Estimated)
September 1, 2025
Study Completion (Estimated)
September 1, 2025
Study Registration Dates
First Submitted
May 27, 2021
First Submitted That Met QC Criteria
June 9, 2021
First Posted (Actual)
June 10, 2021
Study Record Updates
Last Update Posted (Actual)
January 31, 2024
Last Update Submitted That Met QC Criteria
January 30, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Other Study ID Numbers
- R01HL146772 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sleep
-
University of Wisconsin, MadisonPhilips HealthcareCompletedSleep, Slow-wave Sleep, Sleep Enhancement, Sleep Optimization
-
Brain Electrophysiology Laboratory CompanyRecruiting
-
University GhentEuropean CommissionEnrolling by invitation
-
Northumbria UniversityCompletedSleep | Mood | Poor Quality Sleep | Good Sleep HabitUnited Kingdom
-
Baylor College of MedicineEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruiting
-
Brain Electrophysiology Laboratory CompanyCompletedSleep | Sleep HygieneUnited States
-
Koko Home, Inc.Stanford UniversityRecruitingSleep Disorder | Insomnia | Sleep Initiation and Maintenance Disorders | Sleep | Sleep Disturbance | Sleep HygieneUnited States
-
Medical College of WisconsinChildren's Hospital and Health System Foundation, Wisconsin; Divine Savior...Active, not recruitingSleep | Sleep HygieneUnited States
-
Aretaieion University HospitalRecruitingSleep Disorder | Sleep Initiation and Maintenance Disorders | Sleep | Sleep Disturbance | Surgery | Anesthesia | Sleep Fragmentation | Sleep Disorders, Circadian RhythmGreece
-
ResMedCRI-The Clinical Research Institute GmbH; University Hospital RegensburgCompletedObstructive Sleep Apnea | Central Sleep Apnea | Mixed Sleep Apnea | Complex Sleep ApneaSwitzerland, Spain, Denmark, Portugal, France, Germany
Clinical Trials on Morning bright light
-
State University of New York at BuffaloOncology Nursing SocietyUnknownFatigue | Sleep Disturbance | Circadian DysregulationUnited States
-
Portland VA Medical CenterOregon Health and Science UniversityRecruitingBrain Injuries, Traumatic | Post-traumatic Stress DisorderUnited States
-
Rush University Medical CenterCompleted
-
VA Office of Research and DevelopmentRecruiting
-
Guangzhou Psychiatric HospitalUnknownDepressive Disorder | Light TherapyChina
-
Psychiatric Hospital of the University of BaselUnknown
-
China Medical University HospitalNot yet recruiting
-
University of ArizonaU.S. Army Medical Research Acquisition ActivityCompletedConcussion, Mild | Sleep Problems | Post-Concussion SymptomsUnited States
-
University of ArizonaU.S. Army Medical Research Acquisition ActivityCompletedConcussion, Mild | Sleep Problems | Post-Concussion SymptomsUnited States
-
Yale UniversityCompletedCircadian Rhythm Sleep Disorder, UnspecifiedUnited States